From the latest Ataxia UK Newsletter:
Scientists report a significant step toward combatting two degenerative brain diseases. A targeted therapy developed by scientists at University of Utah Health slows the progression of Spinocerebellar Ataxia type 2 (SCA2) in a mouse model of this condition. In a parallel collaborative study, led by researchers at Stanford University, a nearly identical treatment improves the health of mice that model Amyotrophic Lateral Sclerosis (ALS).
Read the press release here: